Smart drug shows promising results for treatment of metastatic triple-negative breast cancer
Full article:

THIS INFORMATION HAS BEEN UPDATED on 04/27/20:  Based on the results from the study reviewed in this XRAY, the U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan-hizy (Trodelvy), as a treatment for people with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. 

We report results of an early-stage clinical trial of a new class of drugs for metastatic triple-negative breast cancer (TNBC). IMMU-132 is a combination of two different molecules: an antibody that targets certain types of cancer and delivers a chemotherapy drug that can kill cancer cells. This study looks at whether IMMU-132 is safe and effective for treating metastatic TNBC. (4/16/19)

Questions To Ask Your Health Care Provider


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.